Da bin ich noch einmal mit weitern News aus UK:
-----------------------------------------------------
LONDON (AFX) - Australian biotech company Phosphagenics Limited announced today that interim results from clinical trials had demonstrated that it had successfully delivered insulin through the skin in humans.
The company said its TPM-02/Insulin product, applied as a gel, was shown to safely penetrate human skin and then be delivered into the blood stream over a sustained period of time.
Phosphagenics said this could potentially radically alter patient care for many diabetics around the world, especially those with Type 2.
The company says there are some 194 million diabetics in the world, the majority of whom are classified as Type 2. The world pharmaceutical market for diabetes is estimated to be worth more than 18 bln usd per annum, it added.
Das ist doch einmal ein mögliches Marktvolumen: 18 bln usd
-----------------------------------------------------
Insulin trial success boosts Phosphagenics
Thu 24 Aug 2006
LONDON (SHARECAST) - Phosphagenics continued its recent good run today after the biotech based in Melbourne, Australia reported successful interim results from its phase I transdermal insulin clinical trial.
The AIM-listed company said the trial showed that it had successfully delivered insulin through the skin in a way that could alter patient care for many diabetics, especially those with Type 2.
From one topical application of TPM-02/Insulin applied as a gel, insulin was shown to safely penetrate the human skin and then be delivered into the blood stream over a sustained period of time.
"The primary objective was to confirm the safety and tolerability of TPM-02/ Insulin, and this was achieved with no adverse reactions," said Dr William Hsu, co-investigator for the trial and clinician at the Joslin Diabetes Center of the Harvard Medical School, Boston, USA
"This technology could eventually transform and expand the world's multi-billion dollar insulin market by providing a non-invasive and effective treatment for many of the world's 194m diabetics, the majority of which are classified as Type 2," he added.
Also, Deine Shares noch nicht verkaufen...